ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

MNPR Monopar Therapeutics Inc

0.65
-0.0101 (-1.53%)
May 01 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Monopar Therapeutics Inc MNPR NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.0101 -1.53% 0.65 15:22:44
Open Price Low Price High Price Close Price Previous Close
0.65 0.635749 0.675 0.65 0.660101
more quote information »

Recent News

Date Time Source Heading
4/18/202407:00GLOBEMonopar Announces Radiopharma Presentation Selected for..
4/16/202407:00GLOBEMonopar Announces Filing of Patent Protecting MNPR-101..
4/10/202407:00GLOBEMonopar Initiates Radiopharma Phase 1 Clinical Trial for..
3/28/202406:00GLOBEMonopar Reports Fourth Quarter and Full-Year 2023 Financial..
3/07/202407:30EDGAR2Form 8-K - Current report
3/05/202406:00EDGAR2Form 8-K - Current report
3/05/202406:00GLOBEMonopar Announces Positive Preclinical Therapeutic Isotope..
2/28/202412:45EDGAR2Form 8-K - Current report
2/27/202406:00GLOBEMonopar Provides Update on MNPR-101-Zr Radiopharma Clinical..
2/27/202405:59EDGAR2Form 8-K - Current report
2/22/202406:00EDGAR2Form 8-K - Current report
2/22/202406:00GLOBEMonopar Announces Promising Preclinical Data for its..
2/20/202407:00EDGAR2Form 8-K - Current report
2/20/202407:00GLOBEMonopar Receives Clearance to Proceed with First-in-Human..
1/03/202418:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
1/03/202418:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/09/202306:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/09/202306:00EDGAR2Form 8-K - Current report
11/09/202306:00GLOBEMonopar Therapeutics Reports Third Quarter 2023 Financial..
11/01/202306:00EDGAR2Form 8-K - Current report
11/01/202306:00GLOBEMonopar Presents Data Showing Tumor Reduction Benefit of..
10/10/202306:00GLOBEMonopar to Participate in the Roth MKM 2023 Healthcare..
10/03/202318:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/03/202318:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
9/05/202306:00GLOBEMonopar to Participate in the H.C. Wainwright 25th Annual..
8/30/202316:16EDGAR2Form 8-K - Current report
8/10/202306:00EDGAR2Form 8-K - Current report
8/10/202306:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
8/10/202306:00GLOBEMonopar Therapeutics Reports Second Quarter 2023 Financial..
8/08/202306:00EDGAR2Form 8-K - Current report
8/08/202306:00GLOBEMonopar Provides Encouraging Camsirubicin Clinical Data..
7/11/202306:00EDGAR2Form 8-K - Current report
7/11/202306:00GLOBEMonopar Announces MNPR-101 Radiopharma Collaboration..
7/03/202317:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
7/03/202317:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
6/28/202315:13EDGAR2Form 8-K - Current report
6/21/202306:00GLOBEMonopar to Participate in the Radiopharma Forum by the Lake..
6/14/202306:00GLOBEMonopar to Participate in the Maxim Group’s Healthcare..
6/01/202306:00GLOBEMonopar Announces Encouraging Camsirubicin Phase 1b Trial..
5/11/202306:00GLOBEMonopar Therapeutics Reports First Quarter 2023 Financial..

Your Recent History

Delayed Upgrade Clock